PPZ1-TORC1 Pathway Links Ferroptosis and Antifungal Resistance in Candida albicans

Study Background and Research Question

Candida albicans is a common fungal pathogen responsible for a range of infections, from superficial oral candidiasis to life-threatening invasive candidemia. The emergence of antifungal resistance, often linked to biofilm formation and limited therapeutic options, drives an urgent need for innovative treatment paradigms. Ferroptosis—a regulated, iron-dependent form of cell death characterized by the accumulation of lipid peroxides—has transformed research on mammalian cell death and tissue injury, but its role in fungal biology has remained largely unexplored. The reference study (Miao et al., 2025) specifically addresses the unresolved question: How does the fungus-specific phosphatase PPZ1 control ferroptosis sensitivity and antifungal resistance in C. albicans, particularly via the TORC1 pathway?

Key Innovation from the Reference Study

The central innovation of this research lies in identifying a mechanistic link between the PPZ1-TORC1 signaling pathway and ferroptosis in C. albicans. While ferroptosis has been widely studied in mammalian systems, its presence and regulatory mechanisms in fungi were unclear. The study demonstrates that exposure to the lipophilic oxidant tert-butyl hydroperoxide (t-BuOOH) induces iron-dependent lipid peroxidation and ferroptotic death in C. albicans—a process tightly regulated by PPZ1 and the downstream TORC1 complex. This mechanistic insight suggests that targeting fungal ferroptosis could be leveraged to sensitize C. albicans to conventional antifungals and potentially overcome resistance.

Methods and Experimental Design Insights

The research combined genetic, pharmacological, and biochemical approaches to dissect the PPZ1-TORC1 pathway's role in ferroptosis and antifungal tolerance. Major methodological highlights include:

• Genetic deletion of PPZ1 in C. albicans to analyze its effect on sensitivity to t-BuOOH-induced cell death.
• Lipid peroxidation assays to quantify iron-dependent oxidative membrane damage, a hallmark of ferroptosis.
• Assessment of TORC1 pathway activity via phosphorylation status of downstream effectors.
• Autophagic flux monitoring to evaluate the interplay between autophagy and ferroptosis sensitivity.
• Drug susceptibility testing to determine the impact of PPZ1-TORC1 modulation on antifungal resistance.

By integrating these tools, the study robustly established causality between PPZ1 function, TORC1 signaling, and the cellular response to ferroptotic stress.

Core Findings and Why They Matter

Key findings from the reference study include:

• Ferroptosis exists in C. albicans and is induced by t-BuOOH: Exposure to t-BuOOH led to the accumulation of iron-dependent lipid peroxides and cell death, fulfilling the biochemical criteria for ferroptosis.
• PPZ1 deletion sensitizes C. albicans to ferroptosis: Knockout mutants lacking PPZ1 had impaired TORC1 activity, higher autophagic flux, and increased sensitivity to t-BuOOH-induced ferroptotic death.
• Disrupted PPZ1-TORC1 signaling reduces antifungal resistance: The same mutants displayed greater susceptibility to several antifungal drugs, suggesting the pathway's broader relevance to clinical resistance mechanisms.
• Interplay between autophagy and ferroptosis: Loss of PPZ1 not only impairs TORC1 signaling but also activates autophagy, which contributes to altered cell death dynamics and drug responses.

These findings position ferroptosis as a modifiable death pathway in C. albicans, regulated by a fungus-specific signaling node. Therapeutically, targeting this axis could both trigger fungal cell death via lipid peroxidation and sensitize pathogens to existing antifungals, offering a dual-pronged strategy to overcome resistance.

Comparison with Existing Internal Articles

Most prior research and reviews—such as "Liproxstatin-1: Precision Ferroptosis Inhibition in Organ Injury Models"—have focused on the role of ferroptosis and its inhibition in mammalian systems, particularly in renal and hepatic injury. These articles emphasize the value of potent ferroptosis inhibitors like Liproxstatin-1 for dissecting iron-dependent cell death and modulating lipid peroxidation in mammalian contexts. For example, "Liproxstatin-1: Potent Ferroptosis Inhibitor with IC50 22 nM" elaborates on the use of Liproxstatin-1 in protecting GPX4-deficient cells and preventing pathological lipid peroxidation. The current reference study broadens this paradigm to pathogenic fungi, demonstrating that similar molecular mechanisms—iron overload, ROS generation, and lipid peroxidation—also underpin regulated cell death in C. albicans. While the specific regulatory proteins (like PPZ1) are fungus-specific, the conceptual framework of ferroptosis and its inhibition remains directly relevant. This cross-kingdom extension underscores the versatility of ferroptosis research tools and the translational promise of lipid peroxidation modulation across diverse biological systems.

Limitations and Transferability

Despite its strengths, the study has several limitations:

• Fungal specificity: The PPZ1-TORC1 pathway is unique to fungi, limiting direct extrapolation to mammalian ferroptosis regulation. However, the biochemical markers of ferroptosis (iron-dependent lipid peroxidation, ROS) are conserved.
• Model constraints: Most experiments were conducted in vitro or with engineered deletion strains. The in vivo relevance of PPZ1-TORC1-mediated ferroptosis in clinical or animal infection models remains to be explored.
• Therapeutic translation: While the study proposes ferroptosis induction as an antifungal strategy, the safety and specificity of such interventions (especially in human hosts) require further investigation.

Nevertheless, the work establishes a solid mechanistic foundation for future studies aiming to exploit ferroptosis pathways in antifungal therapy.

Protocol Parameters

• t-BuOOH exposure: Use t-BuOOH at concentrations sufficient to induce lipid peroxidation and ferroptosis in C. albicans; titrate based on pilot dose-response curves.
• PPZ1 deletion: Generate PPZ1 knockout mutants via homologous recombination or CRISPR/Cas9, confirming deletion by PCR and phenotype assays.
• Lipid peroxidation quantification: Employ fluorescent lipid peroxidation probes (such as BODIPY 581/591 C11) to monitor oxidative membrane damage.
• TORC1 activity assessment: Detect phosphorylation status of downstream effectors (e.g., Sch9) using specific antibodies.
• Drug sensitivity assays: Perform standard broth microdilution or spot assays to assess antifungal susceptibility in wild-type and mutant backgrounds.

These parameters reflect established approaches in the reference study and can be adapted for related fungal or mammalian ferroptosis workflows.

Research Support Resources

Researchers investigating ferroptosis in C. albicans or other systems can leverage potent ferroptosis inhibitors to dissect lipid peroxidation dynamics or validate the specificity of cell death pathways. Liproxstatin-1 (SKU B4987) is a widely used small-molecule inhibitor with demonstrated efficacy in blocking ferroptosis and inhibiting lipid peroxidation in both mammalian and fungal models, as confirmed by the product information and recent literature. Integrating Liproxstatin-1 into experimental designs enables precise modulation of ferroptotic processes and supports the translation of mechanistic insights from basic research to antifungal strategy development. APExBIO provides Liproxstatin-1 for research use, with detailed handling and storage guidance to ensure experimental reproducibility.